View Breakthrough2021 On-Demand

This video, presented during ArisGlobal’s Breakthrough 2021 virtual event, provides an executive-level overview of the state of digital transformation, AI adoption, and strategic priorities within the life sciences and digital health communities. Sankesh Abhijeet, President and CEO of ArisGlobal, frames the current landscape as a momentous time for innovation, despite the challenges posed by the global pandemic. The core message centers on the necessity of accelerating the drug creation lifecycle and leveraging advanced technology to improve patient outcomes and ensure robust safety protocols.

A significant theme highlighted is the current digital maturity gap within the industry. The CEO cites survey data indicating that only five percent of companies are currently utilizing cognitive automation. This low adoption rate signifies that, broadly speaking, the life sciences sector is still in the very early stages of advanced digital transformation. This finding underscores a massive opportunity for specialized technology firms to introduce sophisticated AI and machine learning solutions to move organizations beyond basic automation and into true cognitive capabilities that drive complex decision-making and process optimization.

To address this maturity gap and the inherent inefficiencies of traditional processes, the presentation introduces the concept of an "integrated drug creation platform." This framework is designed to collapse traditionally multi-year, multi-stage processes into a single, cohesive step. The goal of this integration is dramatic time reduction, shifting the timeline for drug creation from years down to weeks or months. This acceleration is critical for competitive advantage and for rapidly responding to public health needs, emphasizing the strategic value of unified data environments and intelligent automation across the R&D and regulatory spectrums.

Finally, the discussion touches upon the broader strategic vision for the pharmaceutical sector, emphasizing that "treatment extends beyond the pill." This perspective signals a shift toward holistic patient care models that incorporate digital health solutions, real-world evidence, and comprehensive safety monitoring. The speaker specifically notes that it is a "momentous time for safety," highlighting the critical and evolving role of pharmacovigilance and regulatory compliance in the era of accelerated drug development and advanced digital tools.

Key Takeaways: • Low Cognitive Automation Adoption: The life sciences industry exhibits a significant digital maturity gap, with only five percent of surveyed companies currently utilizing cognitive automation technologies. This indicates that the vast majority of organizations are still operating below the threshold of advanced AI integration, creating a substantial market opportunity for specialized consulting and software development focused on intelligent automation. • The Need for Accelerated Drug Creation: The industry mandate is to drastically reduce the time required to bring treatments to market. The integrated drug creation platform methodology aims to transform timelines from multi-year cycles into processes achievable within weeks or months by unifying disparate systems and automating complex workflows. • Integrated Platform Strategy: The concept of collapsing multiple steps into a "single step" via an integrated platform is the strategic path forward for efficiency. This requires robust data engineering and system integration services to ensure seamless data flow across R&D, clinical, commercial, and safety operations. • Strategic Focus on Safety and Pharmacovigilance: Despite the push for speed, regulatory safety remains a paramount concern. The emphasis on a "momentous time for safety" highlights the need for AI-powered solutions that can handle the increased volume and complexity of safety data generated by accelerated trials and post-market surveillance. • Shifting Treatment Paradigm: The industry is moving toward a model where "treatment extends beyond the pill," necessitating the integration of digital health, patient engagement tools, and real-world data collection into commercial and medical affairs strategies. This requires solutions like Medical Info Chatbots and Generative AI Sales Ops Assistants to support these holistic approaches. • Digital Transformation is Nascent: The low adoption rate of cognitive automation confirms that the industry is still in the "early stages" of true digital transformation, suggesting that foundational services like data pipeline construction, business intelligence, and basic system integration are still high-demand services. • Opportunity for AI Consulting: The gap between the current 5% adoption rate and the required speed of innovation necessitates external expertise in AI and LLMs to design and implement custom solutions that can handle complex regulatory and scientific data, moving organizations toward true cognitive capabilities. • ArisGlobal’s Ecosystem Role: As the host of the event and a provider of integrated platforms, ArisGlobal is positioning itself as a key partner in this transformation, signaling that partnerships and integrations with major enterprise software providers (like those specializing in Veeva CRM or specific regulatory domains) will be crucial for clients.

Tools/Resources Mentioned:

• Integrated Drug Creation Platform (Conceptual framework)
• Cognitive Automation (Technology category)

Key Concepts:

• Cognitive Automation: Refers to advanced forms of automation that utilize AI, machine learning, and natural language processing (NLP) to perform tasks that typically require human judgment, such as interpreting unstructured data, making predictions, and optimizing complex processes.
• Integrated Drug Creation Platform: A unified technological and process framework designed to streamline and accelerate the entire lifecycle of drug development, from discovery through regulatory submission and post-market safety monitoring, often achieved through centralized data and automated workflows.
• Treatment Beyond the Pill: A strategic shift in the pharmaceutical industry focusing on providing holistic patient solutions that include digital therapeutics, support services, and personalized care, rather than solely relying on the pharmacological product itself.